No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Arrowhead Pharmaceuticals, Inc. is a U.S.-based company focused on developing innovative medicines for the treatment of challenging and difficult-to-treat diseases. The company's extensive development pipeline features several RNA interference (RNAi) therapeutic candidates. These include: ARO-AAT: Currently in Phase II clinical trials for liver diseases associated with alpha-1 antitrypsin deficiency. ARO-APOC3: Advancing through both Phase 2b and Phase 3 clinical studies for hypertriglyceridemia. ARO-ANG3: Undergoing Phase 2b clinical evaluation for dyslipidemia. ARO-HSD: Having successfully completed Phase 1/2 clinical trials for various liver diseases. ARO-ENaC2: In preclinical development for dyslipidemia linked to cystic fibrosis. ARO-C3: In Phase 1/2a clinical trials, designed to reduce the production of complement component 3. ARO-DUX4: A preclinical candidate targeting facioscapulohumeral muscular dystrophy. ARO-XDH: In Phase 1 clinical trials for refractory gout. ARO-COV: A preclinical program focused on COVID-19. ARO-RAGE: In Phase 1/2a clinical trials for muco-obstructive or inflammatory pulmonary conditions. ARO-MMP7: Also in Phase 1/2a clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Beyond its proprietary programs, Arrowhead is actively involved in the development of other significant therapeutics: JNJ-3989: A subcutaneously administered RNAi therapeutic aimed at chronic hepatitis B virus infection. Olpasiran: Designed to decrease the synthesis of apolipoprotein A. ARO-AMG1: Targeting genetically validated pathways for cardiovascular disease. Arrowhead Pharmaceuticals maintains strategic licensing and research collaborations. It partners with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics JNJ-75220795, ARO-JNJ2, and ARO-JNJ3, all of which target liver-expressed pathways. Additionally, the company has a research and license agreement with Takeda Pharmaceuticals U.S.A., Inc. for an RNAi therapeutic candidate intended for liver disease. Established in 1989, Arrowhead Pharmaceuticals, Inc. operates from its corporate headquarters in Pasadena, California.
arrowheadpharma.comNo one on the platform currently holds 0HI3.L.
No tracked institution reports a position in 0HI3.L as of their last filing.
No one on the platform has traded 0HI3.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | -0.8% | — | — | — | ||
| Rev. Growth % | 23258.2% | 56.6% | ||||
| Profit Margin % | -0.2% | -3428.4% | -6925.9% | |||
| Free Cash Flow Margin % | 18.9% | -3421.5% | -6066.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $461M | -39.7% | $-3.55 | $-6.95–$-2.00 | — | 1 |
| 2027 | $343M | -25.6% | $-4.66 | $-9.13–$-2.63 | — | 1 |
| 2028 | $753M | +119.4% | $-2.57 | $-5.04–$-1.45 | — | 1 |
| 2029 | $1.1B | +52.5% | $-0.74 | $-1.44–$-0.41 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $-1.28 | $-1.36 | -6.5% |
| 2026-05-07 | $-1.09 | $-0.93 | +15.0% |
| 2026-02-05 | $0.04 | $0.22 | +491.9% |
| 2025-11-25 | $-0.11 | $-0.17 | -52.4% |
| 2025-08-07 | $-0.95 | $-1.26 | -32.4% |
| 2025-05-12 | $-0.19 | $2.75 | +1567.7% |
| 2025-02-10 | $-0.48 | $-1.39 | -191.3% |
| 2024-11-27 | $-1.12 |
| $-1.37 |
| -22.4% |
| +2.26% |
| $12.9B |
| — |
| 0K1R.LViridian Therapeutics, Inc. | $21.89 | +1.39% | $2.0B | — |
| 0L3C.LHenry Schein, Inc. | $87.95 | +0.08% | $10.2B | — |
Source: Financial Modeling Prep · peers by sector/industry